A phase I clinical research also supported that Ivuxolimab (a TNFRSF4 agonist) showed well tolerance and effective anti-tumor capacity in locally advanced or metastatic cancers, including HCC [37]. Here, TNFRSF4 is linked to metastatic malignant neoplasm.